Histone hyperacetylating agents for promoting wound healing and preventing scar formation
A method for promoting wound healing and preventing scar formation in a variety of wounds in skin, mucosa, and cornea. The method comprises administering a therapeutically effective amount of a histone deacetylase inhibitor or a hyperacetylating agent. The histone deacetylase inhibitor or hyperacetylating agent is capable of stimulating multiple cytokines/growth factors in the early phase of wound healing, and suppressing fibrogenic cytokines/growth factors in the late phase of tissue remodeling in the wound site, and is useful in promoting epithelial cell re-growth and reducing excessive collagen accumulation, which results in rapid wound closure with reduced scaring.
1. A method for promoting a wound healing process in skin, mucosa, or cornea, comprising applying to a wound in a subject in the inflammation phase or the tissue forming phase of the wound healing process a pharmaceutical composition including a therapeutically effective amount of a histone deacetylase inhibitor or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, wherein the histone deacetylase inhibitor is selected from the group consisting of trichostatin A, trichostatin C, sodium butyrate, isovalerate, valerate, 4-phenylbutyrate, sodium phenylbutyrate, propionate, butyramide, isobutyramide, phenylacetate, 3-bromopropionate, valproic acid, valproate, and tributyrin, and wherein the wound is selected from the group consisting of ulcer resulting from a chemical injury, phototoxic reactions, ulcer from an infectious process, desquamation resulting from drug eruption, oral aphthae, contact and irritant stomatitis, and dental erosion.
2. The method of claim 1 , wherein the pharmaceutical composition is administered non-orally.
3. The method of claim 1 , wherein the histone deacetylase inhibitor is present in an amount of from about 0.0001% to about 100% by weight of the composition.
4. The method of claim 1 , wherein the pharmaceutical composition is a cream, an ointment, a gel, a paste, a powder, an aqueous solution, a spray, a suspension, a dispersion, a salve, a lotion, a patch, a suppository, a liposome formation, a mouth wash, an enema, an injection solution, an eye drop, an ear drop, a drip infusion, a microcapsule, or a nanocapsule.
5. The method of claim 1 , wherein the pharmaceutical composition further comprises at least one agent selected from the group consisting of a cytokine, an interleukin, a growth factor, an angiogenic agent, an anti-neoplastic agent, an anti-inflammatory agent, a steroid, an immunosuppressive agent, an analgesic agent, an antipruritic agent, an antibacterial agent, an antiviral agent, an antifungal agent, an antiparasitic agent, an anti-oxidant agent, retinoic acid, an anti-fibrogenic agent, a vasoactive agent, an antibody, a conjugated antibody, an adenosine receptor agonist, and a peroxisome proliferating activator receptor (PPAR) agonist.
6. The method of claim 5 , wherein the growth factor is selected from the group consisting of epidermal growth factor (EGF), fibroblast growth factor (FGF), keratinocyte growth factor (KGF), transforming growth factor-alpha (TGF-α), transforming growth factor-beta (TGF-β), platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), insulin-like growth factor (IGF), and granulocyte macrophage-colony stimulating factor (GM-CSF).
7. The method of claim 5 , wherein the cytokine is selected from the group consisting of interleukin-1, tumor necrosis factor-alpha (TNF-α), and interleukin-6.
8. The method of claim 5 , wherein the angiogenic agent is selected from the group consisting of VEGF, TGF-β, basic FGF, angiogenin, angiopoietin 1, and thrombospondin.
9. The method of claim 5 , wherein the anti-oxidant agent is vitamin C, vitamin E, or superoxide dismutase.
10. The method of claim 5 , wherein the anti-inflammatory agent is selected from the group consisting of corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), cyclosporine, colchicines, D-penicillamine, and TNF-α antagonists.
11. The method of claim 5 , wherein the anti-fibrogenic agent is selected from the group consisting of interferons, TGF-β antagonists, and angiotensin-converting enzyme inhibitors.
12. The method of claim 5 , wherein the antiviral agent is Ganciclovir, Acyclovir, or Famciclovir.
13. The method of claim 1 , wherein the subject is a human, a dog, a cat, a rat, a hamster, or a mouse.
14. The method of claim 1 , wherein the applying step is performed in the inflammation phase.
15. The method of claim 1 , wherein the applying step is performed in the tissue forming phase.